Author(s):
Honey Joshi, Bhakti Shah
Email(s):
bhaktishah@gmail.com
DOI:
10.52711/0974-360X.2024.00475 
Address:
Honey Joshi1, Bhakti Shah2*
1Department of Science, Shree Swaminarayan College of Science, Swaminarayan University, Kalol, Gandhinagar, Gujarat, India - 382725.
2Department of Pharmaceutics, Shree Swaminarayan College of Pharmacy, Swaminarayan University, Kalol, Gandhinagar, Gujarat, India-382725.
*Corresponding Author
Published In:
Volume - 17,
Issue - 7,
Year - 2024
ABSTRACT:
HPLC is a separation technique used to conduct chromatography. There are various technologies of chromatography in which RP-HPLC is one of them. Reverse phase HPLC is highly valuable in research technique because it uses water based mobile phase in organic solvent. Ruxolitnib is a JAK ½ inhibitor used in the treatment of myelofibrosis. Ruxolitinib gives highly separation in RP-HLPC method. So using this method gives marvelous result with help of different ingredients.(RP-HPLC) method was developed for the quantification of Ruxolitinib zorbax SB (Stable bond) C18 phenyl (150×4.6mm 3.5µm) column was used as stationary phase to separate drug. Mobile phase comprised of ACN: MeOH (50:50) having pH 3.5was run isocratically at a flow rate of 1mL/min at 35ºC. The method was validated according to ICH guidelines for linearity, precision, accuracy,. The method was found accurate, precise with average retention time 15min with regression coefficient R2 value of 0.9996 as per ICH norms, the developed method was successfully validated and used for the quantification of Ruxolitinib in fast dissolving tablets.
Cite this article:
Honey Joshi, Bhakti Shah. Development and Validation of RP HPLC Method for Estimation of Ruxolitinib Tablet in Pharmaceutical Dosage Form. Research Journal of Pharmacy and Technology.2024; 17(7):3040-4. doi: 10.52711/0974-360X.2024.00475
Cite(Electronic):
Honey Joshi, Bhakti Shah. Development and Validation of RP HPLC Method for Estimation of Ruxolitinib Tablet in Pharmaceutical Dosage Form. Research Journal of Pharmacy and Technology.2024; 17(7):3040-4. doi: 10.52711/0974-360X.2024.00475 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2024-17-7-8
REFERENCES:
1. Vainchenker W, Kralovics R. Genetic basisand molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017; 129(6): 667-679.
2. Jakafi® (Ruxolitinib) tablets, for oral use [prescribing information]. Wilmington, DE: Incyte Corporation. Available from: http://www.incyte.com/products/uspi_jakafi.pdf. Accessed September 9, 2013.
3. Rodrigues MA, Torres T. JAK/STAT inhibitors for the treatment of atopic dermatitis. J Dermatolog Treat. 2020; 31: 33–40. https://doi. org/ 10. 1080/ 09546 634. 2019. 15775 49.
4. Solimani F, Meier K, Ghoreschi K. Emerging topical and systemicJAK inhibitors in dermatology. FrontImmunol. 2019; 10: 2847. https:// doi. org/ 10. 3389/ fimmu. 2019. 02847.
5. Howell MD, Kuo FI, Smith PA. Targeting the Janus kinase family in autoimmune skin diseases. Front Immunol. 2019; 10: 2342. https:// doi. org/ 10. 3389/ fimmu. 2019. 02342.
6. Welsch K, Holstein J, Laurence A, Ghoreschi K. Targeting JAK/STAT signalling in inflammatory skin diseases with small moleculeinhibitors. Eur J Immunol. 2017; 47: 1096–107. https:// doi.org/ 10. 1002/ eji. 20164 6680.
7. Rerknimitr P, Otsuka A, Nakashima C, Kabashima K. The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus. Inflamm Regen. 2017; 37: 14. https:// doi. org/ 10. 1186/ s41232- 017- 0044-7.
8. Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017; 139: S65-s76. https:// doi. org/ 10. 1016/j. jaci. 2017. 01. 011.
9. Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016; 15: 35–50. https:// doi. org/10. 1038/ nrd46 24.
10. Rogatsky E. Modern high performance liquid chromatography and HPLC 2016 International Symposium. J Chromatogr Sep Tech. 2016; 7: e135.
11. Mulubwa M, et al. Development and validation of high performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) method for determination of tenofovir in small volumes of human plasma. J Chromatogr Sep Tech. 2015; 6: 300.
12. Santini DA, et al. Development of a high performance liquid chromatography method for the determination of tedizolid in human plasma, human serum, saline and mouse plasma. J Chromatogr Sep Tech. 2015; 6: 270. 14. Lin G, et al. Determination of sodium tanshinone iia sulfonate in rat plasma by high performance liquid chromatography and its application to pharmacokinetics studies. Pharm Anal Acta. 2015; 6: 383.
13. AL-Jammal MKH, et al. Development and validation of micro emulsion high performance liquid chromatography(MELC) method for the determination of nifedipine in pharmaceutical preparation. Pharm Anal Acta. 2015; 6: 347.
14. Myron P, et al. Tributylamine facilitated separations of fucosylated chondroitin sulfate (fucs) by high performance liquid chromatography (HPLC) into its component using 1-phenyl- 3-methyl-5-pyrazolone (pmp) derivatization. J Chromatogr Sep Tech. 2015; 6: 256.
15. Tang M, et al. HPLC analysis of monomer release from conventionally and high temperature high-pressure polymerised urethane dimethacrylate intended for biomedical applications. J Chromatograph Separat Techniq. 2014; 5: 227.
16. Yuri Kazakevich, Rosario Lobrutto. HPLC for pharmaceutical scientists. United States of America. A John Wiley and Sons, Inc, Publication; 2007: 3.
17. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human use. Validation of Analytical Procedures: Text and Methodology ICH Q2 (R1). 2005.
18. Ewing GW. Instrumental methods of chemical analysis, 5th ed., McGraw Hill International Publication. Chemistry Series. 1985: 1-4.